Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort

Phio Pharmaceuticals Corp.

2025-Q2 EPS reported -$0.86

Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.
PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.
July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.
R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.